BioNTech flags return to revenue growth in 2025
Make us a preferred source
Make us a preferred source on Google
The news: Covid-19 vaccine maker BioNTech released 2024 guidance on Tuesday, anticipating total revenues of €3 billion ($4.9 billion) for the year as it focuses on scaling up oncology trials and launches.
The numbers: BioNTech ended 2023 with approximately €17.5 billion in cash, cash equivalents and security investments according to unaudited figures. Should BioNTech’s 2024 total revenue be €3 billion, this would be almost €1 billion below consensus estimates provided by S&P Capital IQ analysts.
The context: A press release from the biotechnology company states that its 2024 revenues will be largely driven by its Covid-19 vaccine franchise, and will continue generating interest income throughout the year. BioNTech plans to ensure its oncology business is commercially ready in multiple countries by the end of 2025.
The source: BioNTech Press Release
